Greenstone LLC Announces Introduction of LATANOPROST Ophthalmic Solution —
Its Latest Generic Pharmaceutical Product
PEAPACK, N.J., May, 2011 — Greenstone LLC, the generic pharmaceutical subsidiary of
Pfizer Inc., is pleased to announce the introduction of LATANOPROST to its everexpanding
generic pharmaceutical product line.
LATANOPROST is the authorized generic of, and thereby fully substitutable for,
Xalatan®. This new generic product from Greenstone is being offered in 125 mcg/2.5 mL
Solution, available in single count and three count cartons.
LATANOPROST, which complements the consistently growing line of products from
Greenstone, is supported by a company heritage of commitment to quality, reliable
manufacturing, and customer-focused attention.
Xalatan® is a registered trademark of Pfizer Inc.
Back to Press Releases
Greenstone LLC, established in 1993, is a wholly owned subsidiary of Pfizer Inc,
one of the largest pharmaceutical companies in the world. Greenstone, which focuses
on customer service, markets a broad line of quality Authorized Generics —
along with an expanding line of ANDA (Abbreviated New Drug Application) generics.
Greenstone Authorized Generics, well known for having the same physical characteristics
as the innovators' brands, are supported by state-of-the-art distribution and operations
services. Greenstone is working with numerous brand pharmaceutical companies to
assist in their "post-exclusivity" planning, with a focus on Authorized Generics.
The company offers a robust product pipeline that highlights quality generic equivalents
to some of the best-selling branded pharmaceuticals. Greenstone LLC will continue
to offer numerous future product opportunities for pharmacies and its trade partners.